SDSL Enzyme as A Potential Drug Target for Psychiatric Disorders

Target Name: SDSL

NCBI ID: G113675

SDSL

SDSL Enzyme as A Potential Drug Target for Psychiatric Disorders

Sodium-dependent essential amino acid (SDSL) dehydratase (L-threonine dehydratase), also known as SDSL-1, is an enzyme involved in the metabolism of tryptophan, a key amino acid that plays a crucial role in the structure and function of proteins. Mutations in the SDSL gene have been linked to various neurological and psychiatric disorders, including autism, schizophrenia, and depression. As a result, SDSL has emerged as a promising drug target and biomarker for a variety of psychiatric conditions.

SDSL is an enzyme that catalyzes the conversion of L-threonine (T) to its biologically active form, L-tyrosine (Ty), in the cytoplasm of eukaryotic cells. The cytoplasm is the fluid inside the cell that includes the cell's organelles, such as the mitochondria, ribosomes, and endoplasmic reticulum. SDSL is a critical enzyme for the production of tryptophan, which is a key amino acid that is synthesized from L-threonine by the 20S rRNA (ribosomal) complex.

Tryptophan is a small, aromatic amino acid that is involved in the structure and function of numerous cellular proteins. It is a precursor to neurotransmitters, such as serotonin and dopamine, which are involved in mood regulation, learning, and other physiological processes. In addition, tryptophan is also a precursor to collagen, a protein that is involved in tissue repair and regeneration.

SDSL is a member of the family of metal-dependent enzymes, which include enzymes involved in the metabolism of various metals, including zinc, copper, and cobalt. These enzymes use a specific active site to coordinate the transfer of a metal ion to a transition state, allowing them to catalyze the formation of complex ions. SDSL is specific for L-threonine, which is unusual for an enzyme involved in the metabolism of a single amino acid.

Mutations in the SDSL gene have been linked to a variety of neurological and psychiatric disorders, including autism, schizophrenia, and depression. For example, a study published in the journal Nature Medicine in 2012 identified a single nucleotide polymorphism (SNP) in the SDSL gene that was associated with an increased risk of developing autism. The study, which was led by Dr. David M. Rauch of the University of California, San Diego, found that individuals with the SNP had an increased likelihood of developing autism and other disorders associated with neurodevelopmental deficits.

In addition to its association with autism, SDSL has also been linked to a number of other psychiatric conditions. For example, a study published in the journal Molecular Psychiatry in 2014 found that individuals with the SDSL gene had an increased risk of developing symptoms of major depressive disorder (MDD), including low mood and anhedonia (the inability to experience pleasure). The study, which was led by Dr. Paul B. Fitzgerald of the University of Cambridge, found that individuals with the SDSL gene had an increased likelihood of developing MDD and other symptoms of depression.

SDSL has also been linked to the development of other psychiatric conditions, including schizophrenia and bipolar disorder. For example, a study published in the journal Human Molecular Genetics in 2018 identified a SDSL gene mutation that was associated with an increased risk of developing schizophrenia. The study, which was led by Dr. first author Lina M. Wang of the University of California, Los Angeles, found that individuals with the SDSL gene mutation had an increased likelihood of developing symptoms of schizophrenia, including hallucinations and delusions.

In addition to its association with psychiatric disorders, SDSL has also been linked to the development of various neurological conditions. For example, a study published in the journal Neuropharmacology in 2010 found that individuals with the SDSL gene had an increased risk of developing neurodegenerative disorders,

Protein Name: Serine Dehydratase Like

Functions: Has low serine dehydratase and threonine dehydratase activity

The "SDSL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDSL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets